CareDx (NASDAQ:CDNA) Releases Quarterly Earnings Results

CareDx (NASDAQ:CDNA) announced its earnings results on Tuesday. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.10), Zacks reports. CareDx had a net margin of 17.97% and a return on equity of 18.03%. CareDx updated its FY 2025 guidance to EPS.

CareDx Price Performance

CDNA traded down $0.25 during trading on Tuesday, reaching $14.52. 1,472,588 shares of the stock were exchanged, compared to its average volume of 1,199,126. The business’s 50 day moving average price is $14.36 and its two-hundred day moving average price is $15.62. The company has a market capitalization of $772.86 million, a price-to-earnings ratio of 14.24 and a beta of 2.37. CareDx has a 1 year low of $10.96 and a 1 year high of $26.37.

Institutional Trading of CareDx

A number of institutional investors have recently bought and sold shares of CDNA. Bamco Inc. NY boosted its position in CareDx by 11.2% during the second quarter. Bamco Inc. NY now owns 2,435,657 shares of the company’s stock worth $47,593,000 after purchasing an additional 245,651 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in CareDx by 18.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock worth $19,703,000 after purchasing an additional 170,504 shares in the last quarter. Meridiem Capital Partners LP purchased a new stake in CareDx during the second quarter worth $2,411,000. First Trust Advisors LP purchased a new stake in shares of CareDx in the second quarter valued at $1,822,000. Finally, Lazard Asset Management LLC lifted its position in shares of CareDx by 642.8% in the second quarter. Lazard Asset Management LLC now owns 102,740 shares of the company’s stock valued at $2,006,000 after acquiring an additional 88,909 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Wall Street Zen downgraded CareDx from a “hold” rating to a “sell” rating in a research note on Tuesday, October 28th. Wells Fargo & Company decreased their price target on CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Friday, August 8th. William Blair assumed coverage on CareDx in a research note on Tuesday, August 26th. They issued a “market perform” rating on the stock. Craig Hallum decreased their price target on CareDx from $40.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Finally, Zacks Research downgraded CareDx from a “hold” rating to a “strong sell” rating in a research note on Monday, October 20th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $25.50.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.